Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zandatrigine extension in focal onset seizures
NCT05493293Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of zandatrigine in focal onset seizure, sponsored by Neurocrine Biosciences. Primary endpoint: Occurrence of Serious Treatment-Emergent Adverse Events at Week 111. Started Nov 2022; status: terminated.
02
Drugs
zandatrigine
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT05493293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493293.